Current and future antiviral agents for chronic hepatitis B

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 3, 2003, Pages 481-485

  Yuen, Man Fung ^a   Lai, Ching Lung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Antivirals; HBV; Hepatitis

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; AMDOXOVIR; ANTIVIRUS AGENT; CLEVUDINE; DEOXYADENOSINE PHOSPHATE; DEOXYCYTIDINE; DEOXYGUANOSINE DERIVATIVE; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; HEPATITIS VACCINE; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PREDNISOLONE; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; STEROID; TENOFOVIR; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESISTANCE; DRUG SAFETY; DRUG STRUCTURE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MONOTHERAPY; NEPHROTOXICITY;

ANIMALS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FORECASTING; HEPATITIS B, CHRONIC; HUMANS;

EID: 0037341628     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg122     Document Type: Article

References (30)

1. Yuen, M. F. & Lai, C. L. (2001). Treatment of chronic hepatitis B. Lancet Infectious Diseases 1, 232-41.
2. Yuen, M. F., Hui, C. K., Cheng, C. C., Wu, C. H., Lai, Y. P. & Lai, C. L. (2001). Long-term follow-up of interferon-alpha treatment in Chinese patients with chronic hepatitis B infection: the effect on HBeAg seroconversion and the development of cirrhosis-related complications. Hepatology 34, 139-45.
3. Lai, C. L., Chien, R. N., Leung, N. W. Y., Chang, T. T., Guan, R., Tai, D. I. et al. (1998). A one-year trial of lamivudine for chronic hepatitis B. New England Journal of Medicine 339, 61-8.
4. Dienstag, J. L., Schiff, E. R., Wright, T. L., Perrillo, R. P., Hann, H. W. L., Goodman, Z. et al. (1999). Lamivudine as initial treatment for chronic hepatitis B in the United States. New England Journal of Medicine 341, 1256-63.
5. Schiff, E. R., Heathcote, J., Dienstag, J. L., Hann, H. W. L., Woessner, M., Brown, N. et al. (2000). Improvement in liver histology and cirrhosis with extended lamivudine therapy. Hepatology 32, 296A.
6. Song, B. C., Suh, D. J., Lee, H. C., Chung, Y. H. & Lee, Y. S. (2000). Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 32, 803-6.
7. Santantonio, T., Mazzola, M., Iacovazzi, T., Miglietta, A., Guastadisegni, A. & Pastore, G. (2000). Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. Journal of Hepatology 32, 300-6.
8. Hadziyannis, S. J., Papatheodoridis, G. V., Dimou, E., Laras, A. & Papaioannou, C. (2000). Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32, 847-51.
9. Yao, F. Y. & Bass, N. M. (2000). Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. Journal of Hepatology 33, 301-7.
10. Kapoor, D., Guptan, R. C., Wakil, S. M., Kazim, S. N., Kaul, R., Agarwal, S. R. et al. (2000). Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. Journal of Hepatology 33, 308-12.
11. Yao, F. Y., Terrault, N. A., Freise, C., Maslow, L. & Bass, N. M. (2001). Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 34, 411-6.
12. Yuen, M. F., Sablon, E., Hui, C. K., Yuan, H. J., Decraemer, H. & Lai, C. L. (2001). Factors predicting hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 34, 785-91.
13. Melegari, M., Scaglioni, P. P. & Wands, J. R. (1998). Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27, 628-33.
14. Ono-Nita, S. K., Kato, N., Shiratori, Y., Masaki, T., Lan, K. H., Carrilho, F. J. et al. (1999). YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 29, 939-45.
15. Hadziyannis, S. J., Papatheodoridis, G. V., Dimou, E., Laras, A. & Papaioannou, C. (2000). Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32, 847-51.
16. Marcellin, P., Goodman, Z., Chang, T. T., Lim, S. G., Tong, M. R., Sievert, W. et al. (2002). Histological improvement in HBeAg positive chronic hepatitis B patients treated with adefovir dipivoxil. Journal of Hepatology 36, Suppl. 1, 8A.
17. Das, K., Xiong, X., Yang, H., Westland, C. E., Gibbs, C. S., Sarafianos, S. G. et al. (2001). Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). Journal of Virology 75, 4771-9.
18. Ying, C., De Clercq, E., Nicholson, W., Furman, P. & Neyts, J. (2000). Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. Journal of Viral Hepatitis 7, 161-5.
19. van Bömmel, F., Wünsche, T., Schürmann, D. & Berg, T. (2002). Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 36, 507.
20. Colonno, R. J., Genovesi, E. V., Medina, I., Lamb, L., Durhan, S. K., Huang, M. L. et al. (2001). Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. Journal of Infectious Diseases 184, 1236-45.
21. Lai, C. L., Rosmawati, M., Lao, J., Vlierberghe, H. V., Anderson, F. H., Thomas, N. et al. (2002). Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 123, 1831-8.
22. Bryant, M. L., Bridges, E. G., Placidi, L., Faraj, A., Loi, A. G., Pierra, C. et al. (2001). Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrobial Agents and Chemotherapy 45, 229-35.
23. Lai, C. L., Lim, S. G., Yuen, M. F., Pow, D. M. & Myers, M. W. (2002). L-DT: an ongoing phase I/II dose escalation trial in patients with chronic HBV infection (NV-02B-001). Journal of Hepatology 34, Suppl. 1, 139A.
24. Chu, C. K., Boundinot, F. D., Peek, S. F., Hong, J. H., Choi, Y., Korba, B. E. et al. (1998). Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent. Antiviral Therapy 3, Suppl. 3, 113-21.
25. Colledge, D., Locarnini, S. A. & Shaw, T. (1997). Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 26, 234-7.
26. De Man, R. A., Marcellin, P., Habal, F., Desmond, P., Wright, T., Rose, T. et al. (2000). The famciclovir hepatitis B study group. A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B. Hepatology 32, 413-7.
27. Lai, C. L., Yuen, M. F., Hui, C. K., Garrido-Lestache, S., Cheng, C. T. K. & Lai, Y. P. (2002). A comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: results of 24 weeks of therapy. Journal of Medical Virology 67, 334-8.
28. Schalm, S. W., Heathcote, J., Cianciara, J., Farrell, G., Sherman, M., Williams, B. et al. (2000). Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 46, 562-8.
29. Schiff, E., Karayalcin, S., Grimm, I., Perrillo, R., Dienstag, J., Husa, P. et al. (1998). A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology 28S, 388A.
30. Liaw, Y. F., Tsai, S. L., Chien, R. N., Yeh., C. T. & Chu, C. M. (2000). Prednisolone priming enhances Th 1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 32, 604-9.